医脉通首页
软件中心
频道导航
资讯
病例
专题
圈子
指南
期刊文献
诊疗知识库
e信使
e讲堂
e调研
会议
医生工具
互助区
登录
注册
搜索词条
新版本
知识库首页
分类索引
我的知识库
霍奇金淋巴瘤 -
推荐文献
概览
简介
名称与编码
精要
历史
致谢
缩略语表
基础
定义
流行病学
病因
病理解剖
病理生理
分类分型
预防
预防
筛检
诊断
问诊与查体
疾病演变
辅助检查
并发症
诊断标准
诊断程序
鉴别诊断
治疗
治疗目标
治疗细则
管理与监测
治疗程序
治疗进展
护理与照顾
随访
随访要点
预后
患者教育
临床资料
诊疗指南
临床路径
病例
临床问题
文献资料
参考文献
网络资源
推荐文献
课件
图片
聚合阅读>>
推荐文献
Lymphoid enhancer binding factor 1 (LEF1) expression is significantly higher in Hodgkin lymphoma associated with Richter syndrome relative to de novo classic Hodgkin lymphoma.
[临床试验]Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
[临床试验]Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors.
[临床试验]Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.
[临床试验]PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
[临床试验]Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results.
Late relapses in Hodgkin lymphoma - should we search for the needle in the haystack?
[临床试验]PET/MRI for staging patients with Hodgkin lymphoma: equivalent results with PET/CT in a prospective trial.
Chidamide and decitabine can synergistically induce apoptosis of Hodgkin lymphoma cells by up-regulating the expression of PU.1 and KLF4.
[病例]Massive Calcification of the Ascending Aorta Secondary to Irradiation for Hodgkin's Disease Decades Earlier in Association with Aortic Valve Stenosis.
The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years.
Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics.
Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in the Netherlands, 1989-2017.
[临床试验]Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.
[临床试验]A multicentre phase-II feasibility study evaluating gemcitabine/vinorelbine / prednisolone combination chemotherapy in relapsed / refractory Hodgkin's lymphoma.
[综述]Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab.
[临床试验]Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
[综述]Stance of MRD in Non-Hodgkin's Lymphoma and its upsurge in the novel era of cell-free DNA.
[综述]Novel treatments in B cell non-Hodgkin's lymphomas.
统计信息
录入日期：2011-05-26
最近更新：2011-10-25
浏览次数：39659
编辑次数：69
我要参编
参编团队
主编
于力
主任医师
中国人民解放军总医院血液科主任，全军血液病中心主任，中华医学会全国血液学会常务委
...
[详情]
赵永强
主任医师
北京协和医院血液内科主任医师，博士生导师。1983年毕业于中山医学院医学系，获学士学
...
[详情]
主要编写者
陆晓琳
药师
更多>>
知识库免责声明
本诊疗知识库所提供的有关疾病检查、诊断、治疗以及预防等所有信息，仅供医生参考和学习，不面向患者，不能代替任何医生的处方和医嘱。
如果你对诊疗知识库有任何建议和意见，请联系
010-64405225
。
关于我们
|
联系我们
|
隐私政策
|
版权声明
|
免责声明
|
公司产品
|
网站帮助
北京医脉互通公司 版权所有
（京）-非经营性-2018-0300
京公网安备
11010502036930
京ICP备
13043379
号-5
京ICP证
130463
号
©
2005-2025 medlive.cn, all rights reserved
